I agree with your analysis. However the street will shoot now and and questions later since we didn't get the data needed for accelerated approval. I am disappointed, but GSK is still backing this platform in a big way, and these orphan diseases are tricky, so a couple missteps along the way are not unexpected. This is a long term spec investment or lottery ticket at best for now. But if they can find the successful formula to fix misfolded proteins (i.e. Parkinsons, Alzheimers), then I want to be there.